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Background:
 
 Recent registries have shown that recommended drugs for
the treatment of congestive heart failure (CHF) remain under-prescribed in
daily practice.
 
Aims:
 
 To compare prescription rates of CHF drugs in three French surveys
Impact Reco I, II and III.
 
Methods:
 
 We included outpatients followed by private cardiologists: 1947
in Impact Reco I (2005), 1974 in Impact Reco II (2005/2006) and 1574 in
Impact Reco III (2007), with NYHA class II-IV heart failure and a left ven-
tricular ejection fraction < 40%, and we compared treatment modalities. Rec-
ommended treatments and target doses were defined according to ESC
guidelines.
 
Results: 
 
There was an improvement in both the rate of prescription, and in
the proportion of patients reaching target dose or 50% of target dose of ACE
I, ARBs and beta blockers (see table
 
)
 
.
 
Conclusion: 
 
We observed an improvement with time in the management
of CHF outpatients with an increase in prescription rates of recommended
CHF drugs, as well as in the dosage used for ACE-I, ARB and beta-blockers,
although there is still room for improvement particularly for beta blockers.
These encouraging findings suggest a better awareness and implementation of
ESC guidelines by French private cardiologists. 
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Background:
 
 Hospitalizations for heart failure (HF) are associated
with high mortality and influence post-discharge survival in patients with both
reduced and preserved (
 
≥
 
50%) ejection fraction (EF). Several factors may pre-
cipitate HF hospitalizations. Heart failure with preserved ejection fraction
(HFPEF) is associated with considerable mortality. The characteristics and
prognostic impact of precipitating factors have not been studied in patients
with HFPEF.
 
Aims:
 
 To study the characteristics and impact on long-term outcome of HF
precipitating factors in patients surviving a first hospitalization for HFPEF.
 
Methods:
 
 We conducted a prospective observational study (11 healthcare
establishments, Somme, France) and included consecutive patients discharged
alive after a first hospitalization for HFPEF. Precipitating factors were col-
lected on admission (acute coronary syndromes [ACS], uncontrolled hyperten-
sion, arrhythmia, worsening of renal function [WRF], non-adherence to
therapy, and pneumonia). Mortality analyses used Cox models. Patients were
followed for 5 years.
 
Results:
 
 The cohort comprised 358 patients (76±10 years, 53% women).
Mean EF was 63±8%. One ore more precipitating factors were identified in
274 patients (76%). The most common were arrhythmia (37%), pneumonia
(16%), ACS (12%), and WRF (12%). Uncontrolled hypertension and non-
adherence to therapy were identified in 9% and 10% of cases, respectively.
Arrhythmia (HR1.35[1.02-1.80];p=0.03) and pneumonia (HR1.44[1.01-
2.07];p=0.05) were independently related to increased 5-year mortality. Com-
pared to patients without precipitating factors (n=84), those with one factor
(n=190; HR 1.67[1.15-2.43];p=0.007) as well as those with 
 
≥
 
2 factors (n=84;
HR 1.59[1.03-2.45];p=0.04) displayed excess 5-year mortality.
 
Conclusion:
 
 Factors that precipitate hospitalizations are frequent among
patients with HFPEF and predict increased long-term mortality. A more atten-
tive management of these factors may translate into survival benefits. 
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Background:
 
 Pulmonary hypertension (PH) is common in patients with
heart failure (HF) but, its relationship to symptoms and prognosis in a broad
representative population of patients with HF has rarely been investigated.
 
Methods:
 
 We interrogated a large database of consecutive referral to a HF
clinic serving a population of 600,000 people. Systolic HF (S-HF) was defined
as a LVEF
 
≤
 
45% and Preserved systolic LV HF (PS-HF) was defined as LVEF
>45% with an NT-proBNP value >400pg/mL. Right Ventricle Systolic Pres-
sure (RVSP) was assessed by the measurement of the tricuspid regurgitation
(TR) peak systolic velocity.
 
Results:
 
 Of 2135 patients referred, 1026 had S-HF, 354 had PS-HF and 533
had an accurate TR velocity measurement. Median (IQR) calculated RVSP for
HF patients was 25 (18-35mmHg). Amongst these patients, 270 had S-HF
 
January 14
 
th
 
, Thursday 2010
Prescription   
IMPACT 
I
2005
IMPACT 
II
2005/2006
IMPACT 
III
2007
Global population  1917 1974 1574
ACE I Number patients 
with prescription
N (%) 1361 (71.0) 1349 (68.3) 1099 (70.2)
Target dose % 48.7 57.3* 52.3•
50% Target dose % 80.4 84.5* 88.4†•
ARBs Number patients 
with prescription
N (%) 395 (20.6) 592 
(30.0)*
516 
(33.3)†•
Target dose % 9.1 7.4 20.7†•
50% Target dose % 52.9 49.7  68.6†•
Beta-
blockers
Number patients 
with prescription
N (%) 1245 (65.2) 1382 
(70.0)*
1229 
(78.3)†•
Target dose % 18.4 23.4*  25.7†
50% Target dose % 47.3 53.5*  59.9†•
* : p<0.05 Impact II vs I 
•: p<0.05 Impact III vs II 
† : p<0.05 Impact III vs I 
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and 143 had PS-HF. Mean age, prevalence of ischaemic heart disease and
arrhythmia were 74+/-10, 52% and 44%. The maximal follow up was 88
months and the median follow up was 65 months. Amongst 1,380 patients with
HF, the 413 with RVSP measurement had a worse prognosis than those who
did not (log Rank=0.0001). Patients in the lowest quartile of RVSP
(<17.5mmHg) had a similar prognosis to the subgroup of HF patients without
TR measurement (16% and 17% at 2 years). Mortality increased as function of
the increase in PH (log Rank=0.005). Quartile of RVSP predicted outcome sim-
ilarly in patients with S-HF and PS-HF. Patients in the highest quartile
of RVSP had a 2 year mortality of 38% if S-HF and 35% if PS-HF. On Cox
proportional hazards multivariate analysis, COPD, Age, logNTproBNP, mean
blood pressure and the highest RVSP quartile were independent predictors of
outcome. 
 
Conclusion:
 
 Patients with heart failure and a TR velocity indicating even
mild pulmonary hypertension have a worse prognosis whether or not LV sys-
tolic function is impaired. Patients with more severe PH have an even worse
outcome. PH is an independent predictor of outcome in HF.
 
067
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Both biologically active BNP1-32 and inactive NT-proBNP1-76 are
released in circulation from prohormone, proBNP1-108. Recent data suggest
that proBNP is detected in blood of heart failure (HF) patients. Blood levels,
kinetics as well as determinants of proBNP1-108 secretion are unknown as
compared to processed forms. We sought to measure and to compare blood
levels of BNP and proBNP in HF and non HF patients.
 
Methods:
 
 plasma natriuretic peptides were assessed in 131 HF patients and
in 36 non-HF patients using both Triage BNP assay and BioRad proBNP
assay. BioRad assay is highly specific of proBNP when the Triage BNP assay
may be influenced by proBNP. Among HF patients, 33 were admitted because
of acute HF and blood samples were analyzed on admission and at discharge.
In order to compare BNP and proBNP levels, results are expressed as nmole/l.
 
Results:
 
 ProBNP was detected in all patients (104 ± 145 nmol/l) and dem-
onstrated a high degree of correlation with BNP in non-HF patients (r = 0.95
[95% IC 0.90 – 0.97], p<0.0001) as well as in HF patients (r = 0.97, [0.95 -
 0.98], p<0.0001). The proBNP/BNP ratio was higher in HF patients as com-
pared to non-HF patients (0.82 ± 0.23 versus 0.62 ± 0.18, p < 0.0001). In
patients with decompensated HF, proBNP/BNP ratio were similar on admis-
sion and at discharge, and changes in both BNP and proBNP were similar
(0.91, [0.82-0.95], p < 0.0001). Interestingly, proBNP/BNP ratio was lower in
the most severe HF patients according to discharge BNP and proBNP/BNP
ratio was negatively correlated with discharge BNP (r = -0.40, [-0.65 – -0.06],
p 0.02).
 
Conclusion:
 
 the intact precursor – proBNP- to both BNP and NT-proBNP
circulates in both HF and non-HF patients and is an important part of the pool
of circulating natriuretic peptides. HF seems to be characterized by a decrease
in proBNP processing but, unexpectedely, at a lesser level in acute and/or
severe HF as compared with less severe HF. Biological and physiological
meanings of our results deserves further studies.
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Background: 
 
Heart Failure (HF) is a frequent and severe disease. Overall
prognosis of systolic HF is poor, and one-year survival rate is lower than most
cancers. For that reason, HF units were progressively created in cardiology
departments according to the European guidelines.
 
Aim: 
 
The aim of this study was to describe the evolution in all-cause in-
hospital mortality in patients hospitalized for HF in the HF clinic created at
René Dubos hospital (Pontoise, France).
 
Methods:
 
 We conducted a descriptive study of all-cause in-hospital mor-
tality in a whole population of 4801 patients hospitalized for HF (range per
year: 248-640 patients) from January 1997 to December 2007 in our HF clinic.
Chi square, test for trend and linear regression were performed.
 
Results:
 
 Our population consisted of 2331 men (48.6%) with a mean age
per year ranging from 67.8 to 75.8 years, and a percentage of patients pre-
senting with systolic HF (LVEF<45%) of 53.8%. There were no significant
differences in terms of sex, diabetes mellitus or LVEF<45%, except for age
and renal insufficiency. All-cause in-hospital mortality rate for patients hospi-
talized for HF appeared to be significantly decreasing during ten-year follow-
up (p<0.0001) (see figure). Moreover we noticed that average length of hos-
pital stay was decreasing during ten-year follow-up (p=0.027, -0.3 day per
year).
 
Conclusion:
 
 Mortality in HF patients was confirmed to be decreasing
during the last ten-year period, thereby confirming the impact of HF care man-
agement on HF prognosis. 
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While the major role played by hypertension (HT) in the genesis of chronic
heart failure (HF) is well known, the main risk factors leading to HF in hyper-
tensive patients remain poorly investigated. O-PREDICT 2 was a multicentre,
observational study conducted with 1537 general practitioners who recruited
4427 consecutive hypertensive outpatients (pts) (mean age 72±9 years; 66%
males). We compared pts with a clinical history of HF (group 1, n=2969) and
without HF (group 2, n=1458, age > 65 yrs).
 
Results:
 
 Sex ratio and age were similar between groups. Duration of HT
was higher (P<.05) in group 1 (14± 8 
 
vs.
 
 11± 8 years in group 2). Blood pres-
sure was lower in group 1, with 49.4% pts having SBP 
 
≥
 
 140 mmHg vs.
60.9% in group 2. The number of cardiovascular risk factors ranged from 0 to
11 with a median of 4 in group 1, and from 0 to 10 with a median of 2 in
group 2; 74.3% of pts in group 1 vs. 45.6% in group 2 had more than 3 risks
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